Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.

Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, Cox TR, Timpson P.

Trends Cancer. 2019 Nov;5(11):724-741. doi: 10.1016/j.trecan.2019.09.010. Epub 2019 Oct 21. Review.

PMID:
31735290
2.

Editor's Note: LOX-Mediated Collagen Cross-linking Is Responsible for Fibrosis-Enhanced Metastasis.

Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, Erler JT.

Cancer Res. 2019 Oct 1;79(19):5124. doi: 10.1158/0008-5472.CAN-19-2419. No abstract available.

PMID:
31575632
3.

Correction: LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution.

Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT.

Cancer Res. 2019 Oct 1;79(19):5123. doi: 10.1158/0008-5472.CAN-19-2420. No abstract available.

PMID:
31575631
4.

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.

Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W; Australian Pancreatic Genome Initiative (APGI), Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P.

Nat Commun. 2019 Aug 12;10(1):3637. doi: 10.1038/s41467-019-10968-6.

5.

LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity.

Zeltz C, Pasko E, Cox TR, Navab R, Tsao MS.

Cancers (Basel). 2019 May 22;11(5). pii: E705. doi: 10.3390/cancers11050705.

6.

The importance of developing therapies targeting the biological spectrum of metastatic disease.

Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, Sahai E, Fingleton B, Stein U, Cox TR, Price JT, Kato Y, Welm AL, Aguirre-Ghiso JA; Board Members of the Metastasis Research Society.

Clin Exp Metastasis. 2019 Aug;36(4):305-309. doi: 10.1007/s10585-019-09972-3. Epub 2019 May 17.

PMID:
31102066
7.

Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment.

Nguyen EV, Pereira BA, Lawrence MG, Ma X, Rebello RJ, Chan H, Niranjan B, Wu Y, Ellem S, Guan X, Wu J, Skhinas JN, Cox TR, Risbridger GP, Taylor RA, Lister NL, Daly RJ.

Mol Cell Proteomics. 2019 Jul;18(7):1410-1427. doi: 10.1074/mcp.RA119.001496. Epub 2019 May 6.

8.

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR.

Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y.

9.

Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis.

Beadnell T, Borriello L, Christenson J, Fornetti J, Guldner I, Hanna A, Kyjacova L, Marinak-Whately K, de Melo Martins PC, Rotinen M, Te Boekhorst V, Cox TR.

Clin Exp Metastasis. 2019 Apr;36(2):119-137. doi: 10.1007/s10585-018-09953-y. Epub 2019 Jan 23.

PMID:
30673912
10.

Recent advances in understanding the complexities of metastasis.

Chitty JL, Filipe EC, Lucas MC, Herrmann D, Cox TR, Timpson P.

Version 2. F1000Res. 2018 Aug 1 [revised 2018 Jan 1];7. pii: F1000 Faculty Rev-1169. doi: 10.12688/f1000research.15064.2. eCollection 2018. Review.

11.

Cancer cells' ability to mechanically adjust to extracellular matrix stiffness correlates with their invasive potential.

Wullkopf L, West AV, Leijnse N, Cox TR, Madsen CD, Oddershede LB, Erler JT.

Mol Biol Cell. 2018 Oct 1;29(20):2378-2385. doi: 10.1091/mbc.E18-05-0319. Epub 2018 Aug 9.

12.

Tumor endothelial marker 8 promotes cancer progression and metastasis.

Høye AM, Tolstrup SD, Horton ER, Nicolau M, Frost H, Woo JH, Mauldin JP, Frankel AE, Cox TR, Erler JT.

Oncotarget. 2018 Jul 10;9(53):30173-30188. doi: 10.18632/oncotarget.25734. eCollection 2018 Jul 10.

13.

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.

Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, Skhinas JN, Collot R, Yang J, Harvey K, Johan MZ, Cooper C, Nair R, Herrmann D, McFarland A, Deng N, Ruiz-Borrego M, Rojo F, Trigo JM, Bezares S, Caballero R, Lim E, Timpson P, O'Toole S, Watkins DN, Cox TR, Samuel MS, Martín M, Swarbrick A.

Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6.

14.

Removing physiological motion from intravital and clinical functional imaging data.

Warren SC, Nobis M, Magenau A, Mohammed YH, Herrmann D, Moran I, Vennin C, Conway JR, Mélénec P, Cox TR, Wang Y, Morton JP, Welch HC, Strathdee D, Anderson KI, Phan TG, Roberts MS, Timpson P.

Elife. 2018 Jul 9;7. pii: e35800. doi: 10.7554/eLife.35800.

15.

Charting the unexplored extracellular matrix in cancer.

Filipe EC, Chitty JL, Cox TR.

Int J Exp Pathol. 2018 Apr;99(2):58-76. doi: 10.1111/iep.12269. Epub 2018 Apr 19. Review.

16.

The extracellular matrix as a key regulator of intracellular signalling networks.

Hastings JF, Skhinas JN, Fey D, Croucher DR, Cox TR.

Br J Pharmacol. 2019 Jan;176(1):82-92. doi: 10.1111/bph.14195. Epub 2018 Apr 19. Review.

PMID:
29510460
17.

Shedding new light on RhoA signalling as a drug target in vivo using a novel RhoA-FRET biosensor mouse.

Nobis M, Herrmann D, Warren SC, Strathdee D, Cox TR, Anderson KI, Timpson P.

Small GTPases. 2018 Mar 21:1-8. doi: 10.1080/21541248.2018.1438024. [Epub ahead of print]

PMID:
29457531
18.

Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.

Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P.

Gastroenterology. 2018 Mar;154(4):820-838. doi: 10.1053/j.gastro.2017.11.280. Epub 2017 Dec 26. Review.

PMID:
29287624
19.

Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology.

Conway JRW, Vennin C, Cazet AS, Herrmann D, Murphy KJ, Warren SC, Wullkopf L, Boulghourjian A, Zaratzian A, Da Silva AM, Pajic M, Morton JP, Cox TR, Timpson P.

Sci Rep. 2017 Dec 4;7(1):16887. doi: 10.1038/s41598-017-17177-5.

20.

Proteomic Characterization of Caenorhabditis elegans Larval Development.

Xia T, Horton ER, Salcini AE, Pocock R, Cox TR, Erler JT.

Proteomics. 2018 Jan;18(2). doi: 10.1002/pmic.201700238. Epub 2017 Dec 27.

PMID:
29178193
21.

The interplay between extracellular matrix remodelling and kinase signalling in cancer progression and metastasis.

Skhinas JN, Cox TR.

Cell Adh Migr. 2018;12(6):529-537. doi: 10.1080/19336918.2017.1405208. Epub 2017 Dec 29. Review.

22.

Transient targeting of the pancreatic cancer stroma as a 'fine-tuned' anti-tumor and anti-metastatic therapy.

Vennin C, Cox TR, Pajic M, Timpson P.

Oncotarget. 2017 Oct 3;8(49):84635-84636. doi: 10.18632/oncotarget.21468. eCollection 2017 Oct 17. No abstract available.

23.

Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease.

Cox TR, Erler JT, Rumney RMH.

Calcif Tissue Int. 2018 Feb;102(2):163-173. doi: 10.1007/s00223-017-0352-6. Epub 2017 Nov 2. Review.

24.

Liver lacerations as a complication of CPR during pregnancy.

Cox TR, Crimmins SD, Shannon AM, Atkins KL, Tesoriero R, Malinow AM.

Resuscitation. 2018 Jan;122:121-125. doi: 10.1016/j.resuscitation.2017.10.027. Epub 2017 Oct 31.

PMID:
29097198
25.

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.

Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, Cowley MJ, Molloy TJ; Australian Pancreatic Cancer Genome Initiative (APGI), Waddell N, Johns A, Grimmond SM, Chang DK, Biankin AV, Sansom OJ, Morton JP, Grey ST, Cox TR, Turchini J, Samra J, Clarke SJ, Timpson P, Gill AJ, Pajic M.

Gut. 2018 Dec;67(12):2142-2155. doi: 10.1136/gutjnl-2017-315144. Epub 2017 Oct 28.

26.

Dynamic Rearrangement of Cell States Detected by Systematic Screening of Sequential Anticancer Treatments.

Koplev S, Longden J, Ferkinghoff-Borg J, Blicher Bjerregård M, Cox TR, Erler JT, Pedersen JT, Voellmy F, Sommer MOA, Linding R.

Cell Rep. 2017 Sep 19;20(12):2784-2791. doi: 10.1016/j.celrep.2017.08.095.

27.

Fibrosis and Cancer: Partners in Crime or Opposing Forces?

Cox TR, Erler JT.

Trends Cancer. 2016 Jun;2(6):279-282. doi: 10.1016/j.trecan.2016.05.004. Epub 2016 May 30.

PMID:
28741525
28.

ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.

Mayorca-Guiliani AE, Madsen CD, Cox TR, Horton ER, Venning FA, Erler JT.

Nat Med. 2017 Jul;23(7):890-898. doi: 10.1038/nm.4352. Epub 2017 Jun 12.

PMID:
28604702
29.

Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.

Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, Melenec P, Walters SN, Del Monte-Nieto G, Conway JR, Nobis M, Allam AH, McCloy RA, Currey N, Pinese M, Boulghourjian A, Zaratzian A, Adam AA, Heu C, Nagrial AM, Chou A, Steinmann A, Drury A, Froio D, Giry-Laterriere M, Harris NL, Phan T, Jain R, Weninger W, McGhee EJ, Whan R, Johns AL, Samra JS, Chantrill L, Gill AJ, Kohonen-Corish M, Harvey RP, Biankin AV; Australian Pancreatic Cancer Genome Initiative (APGI), Evans TR, Anderson KI, Grey ST, Ormandy CJ, Gallego-Ortega D, Wang Y, Samuel MS, Sansom OJ, Burgess A, Cox TR, Morton JP, Pajic M, Timpson P.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8504. doi: 10.1126/scitranslmed.aai8504.

30.

Pre-metastatic niches: organ-specific homes for metastases.

Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, Bissell MJ, Cox TR, Giaccia AJ, Erler JT, Hiratsuka S, Ghajar CM, Lyden D.

Nat Rev Cancer. 2017 May;17(5):302-317. doi: 10.1038/nrc.2017.6. Epub 2017 Mar 17. Review.

31.

Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenografic Tumour Model.

Elyas E, Papaevangelou E, Alles EJ, Erler JT, Cox TR, Robinson SP, Bamber JC.

Sci Rep. 2017 Mar 13;7(1):165. doi: 10.1038/s41598-017-00144-5.

32.

Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.

Chang J, Lucas MC, Leonte LE, Garcia-Montolio M, Singh LB, Findlay AD, Deodhar M, Foot JS, Jarolimek W, Timpson P, Erler JT, Cox TR.

Oncotarget. 2017 Apr 18;8(16):26066-26078. doi: 10.18632/oncotarget.15257.

33.

Multi-Channel Optical Coherence Elastography Using Relative and Absolute Shear-Wave Time of Flight.

Elyas E, Grimwood A, Erler JT, Robinson SP, Cox TR, Woods D, Clowes P, De Luca R, Marinozzi F, Fromageau J, Bamber JC.

PLoS One. 2017 Jan 20;12(1):e0169664. doi: 10.1371/journal.pone.0169664. eCollection 2017.

34.

The role of lysyl oxidase, the extracellular matrix and the pre-metastatic niche in bone metastasis.

Gartland A, Erler JT, Cox TR.

J Bone Oncol. 2016 Jul 1;5(3):100-103. eCollection 2016 Sep.

35.

Nuclear expression of lysyl oxidase enzyme is an independent prognostic factor in rectal cancer patients.

Liu N, Cox TR, Cui W, Adell G, Holmlund B, Ping J, Jarlsfelt I, Erler JT, Sun XF.

Oncotarget. 2016 May 26;8(36):60015-60024. doi: 10.18632/oncotarget.9623. eCollection 2017 Sep 1.

36.

Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.

Cox TR, Gartland A, Erler JT.

Cancer Res. 2016 Jan 15;76(2):188-92. doi: 10.1158/0008-5472.CAN-15-2306. Epub 2016 Jan 5. Review.

37.

Delivering bad news to patients.

Monden KR, Gentry L, Cox TR.

Proc (Bayl Univ Med Cent). 2016 Jan;29(1):101-2.

38.

Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism.

Cox TR, Schoof EM, Gartland A, Erler JT, Linding R.

Data Brief. 2015 Oct 23;5:621-5. doi: 10.1016/j.dib.2015.09.039. eCollection 2015 Dec.

39.

Kinome-wide decoding of network-attacking mutations rewiring cancer signaling.

Creixell P, Schoof EM, Simpson CD, Longden J, Miller CJ, Lou HJ, Perryman L, Cox TR, Zivanovic N, Palmeri A, Wesolowska-Andersen A, Helmer-Citterich M, Ferkinghoff-Borg J, Itamochi H, Bodenmiller B, Erler JT, Turk BE, Linding R.

Cell. 2015 Sep 24;163(1):202-17. doi: 10.1016/j.cell.2015.08.056. Epub 2015 Sep 17.

40.

Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis.

Madsen CD, Pedersen JT, Venning FA, Singh LB, Moeendarbary E, Charras G, Cox TR, Sahai E, Erler JT.

EMBO Rep. 2015 Oct;16(10):1394-408. doi: 10.15252/embr.201540107. Epub 2015 Aug 31.

41.

The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.

Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, Huggins ID, Lang G, Linding R, Gartland A, Erler JT.

Nature. 2015 Jun 4;522(7554):106-110. doi: 10.1038/nature14492. Epub 2015 May 27.

42.

AGE-modified basement membrane cooperates with Endo180 to promote epithelial cell invasiveness and decrease prostate cancer survival.

Rodriguez-Teja M, Gronau JH, Breit C, Zhang YZ, Minamidate A, Caley MP, McCarthy A, Cox TR, Erler JT, Gaughan L, Darby S, Robson C, Mauri F, Waxman J, Sturge J.

J Pathol. 2015 Mar;235(4):581-92. doi: 10.1002/path.4485. Epub 2014 Dec 24.

PMID:
25408555
43.

Molecular pathways: connecting fibrosis and solid tumor metastasis.

Cox TR, Erler JT.

Clin Cancer Res. 2014 Jul 15;20(14):3637-43. doi: 10.1158/1078-0432.CCR-13-1059.

44.

Lysyl oxidase in colorectal cancer.

Cox TR, Erler JT.

Am J Physiol Gastrointest Liver Physiol. 2013 Nov 15;305(10):G659-66. doi: 10.1152/ajpgi.00425.2012. Epub 2013 Sep 5. Review.

45.

LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.

Chang J, Nicolau MM, Cox TR, Wetterskog D, Martens JW, Barker HE, Erler JT.

Breast Cancer Res. 2013;15(4):R67.

46.

LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis.

Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, Erler JT.

Cancer Res. 2013 Mar 15;73(6):1721-32. doi: 10.1158/0008-5472.CAN-12-2233. Epub 2013 Jan 23.

47.

Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis.

Baker AM, Bird D, Welti JC, Gourlaouen M, Lang G, Murray GI, Reynolds AR, Cox TR, Erler JT.

Cancer Res. 2013 Jan 15;73(2):583-94. doi: 10.1158/0008-5472.CAN-12-2447. Epub 2012 Nov 27.

48.

The rationale for targeting the LOX family in cancer.

Barker HE, Cox TR, Erler JT.

Nat Rev Cancer. 2012 Jul 19;12(8):540-52. doi: 10.1038/nrc3319. Review.

PMID:
22810810
49.

Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK.

Baker AM, Bird D, Lang G, Cox TR, Erler JT.

Oncogene. 2013 Apr 4;32(14):1863-8. doi: 10.1038/onc.2012.202. Epub 2012 May 28.

PMID:
22641216
50.

The pre-metastatic niche: is metastasis random?

Cox TR, Gartland A, Erler JT.

Bonekey Rep. 2012 May 2;1:80. doi: 10.1038/bonekey.2012.80. eCollection 2012. Review.

Supplemental Content

Support Center